Stay updated on I-SPY Trial: Personalized Breast Cancer Clinical Trial

Sign up to get notified when there's something new on the I-SPY Trial: Personalized Breast Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the I-SPY Trial: Personalized Breast Cancer Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    8 days ago
    No Change Detected
  3. Check
    15 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error instead of the study record content and navigation, blocking access to the trial details. This indicates access is blocked for the study page.
    Difference
    26%
    Check dated 2026-09-20T00:43:57.000Z thumbnail image
  4. Check
    29 days ago
    Change Detected
    Summary
    A publication entry for Cemiplimab and Fianlimab with neoadjuvant chemotherapy in early-stage ERBB2-negative breast cancer (I-SPY2) was updated to include online-ahead-of-print status and the e262576 article number, replacing the previous citation.
    Difference
    0.0%
    Check dated 2026-09-05T22:22:59.000Z thumbnail image
  5. Check
    36 days ago
    Change Detected
    Summary
    Revision updated from v3.6.5 to v3.6.6, representing a minor update to the Study Details page.
    Difference
    0.0%
    Check dated 2026-08-29T19:24:24.000Z thumbnail image
  6. Check
    43 days ago
    Change Detected
    Summary
    A medRxiv preprint by Magbanua et al. on circulating tumor DNA as a prognostic factor in neoadjuvant breast cancer therapy was added to the Publications list, expanding the study's biomarker references.
    Difference
    0.0%
    Check dated 2026-08-22T18:35:32.000Z thumbnail image
  7. Check
    57 days ago
    Change Detected
    Summary
    The page now shows a 500 error page with a minimal HTML structure. The original study content and navigation were removed, leaving the page unavailable.
    Difference
    25%
    Check dated 2026-08-08T15:49:50.000Z thumbnail image
  8. Check
    64 days ago
    Change Detected
    Summary
    A new publication citation has been added to the Publications section, listing authors and the JAMA Oncol article on Cemiplimab and Fianlimab with neoadjuvant chemotherapy in early-stage high-risk ERBB2-negative breast cancer (I-SPY2). This update expands the study's referenced literature and documents ongoing dissemination of trial findings.
    Difference
    0.0%
    Check dated 2026-08-01T14:44:32.000Z thumbnail image

Stay in the know with updates to I-SPY Trial: Personalized Breast Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the I-SPY Trial: Personalized Breast Cancer Clinical Trial page.